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www.cdatm.orgAbstractBackground: Permanent polymer drug eluting stents (PP-DES) may induce inflammation of the vessel wall due to the existence of
the polymer, which may delay intimal healing. Polymer-free DES (PF-DES) that eliminate the polymeric carrier may potentially
lead to safer DES. However, the safety and efficacy of PF-DES remains controversial.
Methods: Randomized controlled trials comparing PF-DES with PP-DES were searched in online database including MEDLINE,
Excerpta Medica Database (EMBASE) and Cochrane Library. Studies reporting late lumen loss (LLL), all-cause death, myocardial
infarction (MI), target lesion revascularization (TLR) and late stent thrombosis (LST) were enrolled and quantitatively analyzed.
Results: Ten studies enrolling 6575 patients were included in this meta-analysis. The PF-DES showed a benefit in reducing all-cause
death (OR¼ 0.77, 95%CI: 0.61 to0.98,P¼0.03) and long-termLLL (weightedmeandifference (WMD)0.16mm,95%CI:0.22 to
0.11 mm, P < 0.001), while no superiority was found in reducing short-term LLL (WMD 0.03 mm, 95% CI: 0.07e0.13 mm,
P¼0.57),MI (OR¼1.12, 95%CI: 0.19 to23.18,P¼0.39),TLR(OR¼1.19,95%CI: 0.42 to3.38,P¼0.83) andLST (OR¼0.92, 95%
CI: 0.05 to 5.71, P¼ 0.74).
Conclusion: PF-DES showed benefits in reducing long-term LLL and mortality compared with PP-DES, but no superiority was
found in short-term LLL,MI, TLR and LST. These findings provide a sound basis for the wide application of PF-DES in the future.
© 2016 ChineseMedical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
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Drug eluting stents (DES) coated with anti-
proliferative agents have been proven to reduce the inci-
dence of restenosis and target lesion revascularization
(TLR) by inhibition of neointimal hyperplasia.1,2 How-
ever, DES are also associated with a higher rate of late
stent thrombosis (LST) as compared with bare metal
stents (BMS).3,4
A permanent polymer coating is used to bind the
anti-proliferative drugs to the stent platform and
control the drug release. The polymer stays in situ
after the drug is released, which can cause chronic
inflammation and can delay the endothelial healing.5,6
Therefore, efforts have been made to develop stents
with biodegradable polymers or with polymer-free
surfaces. There have been several studies of whether
polymer-free stents can produce a better clinical
outcome compared with permanent polymer stents but
there are conflicting results about the clinical
outcomes.
This meta-analysis aims to summarize the data from
randomized controlled trials (RCT) comparing per-
manent polymer DES (PP-DES) with polymer-free
DES (PF-DES).Fig. 1. Flow diagram ofMethods
Search strategy
The meta-analysis was performed according to the
Cochrane handbook for systematic reviews of in-
terventions 5.1.0.7 A systematic review was performed
in MEDLINE, EMBASE, Cochrane Library, Scopus,
Highwire Press and Google Scholar databases for
publications until December, 2015. The search was
conducted without language restriction by two inde-
pendent investigators using the keywords “stent”, “drug
eluting”, “polymer-free”, “nonpolymer”, “polymer” and
“randomized”. Endnote X6 was used to build a library
of references and to erase duplicated results. Meeting
abstracts that provided sufficient data were also
included. Studies with overlapping data were excluded.
Selection criteria
The citations were screened at the title and abstract
level then retrieved as full reports. Inclusion criteria
included the following: 1) RCTs comparing PF-DES
with PP-DES; 2) studies reporting clinical outcomes
as all-cause death and/or cardiac death and/or
myocardial infarction (MI) and/or TLR and/or LSTthe review process.
Fig. 2. Risk of bias judgment.
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definition8 and/or in-stent late lumen loss (LLL) and 3)
a follow-up period longer than six months with or
without quantitative coronary angiography reexami-
nation. Exclusion criteria were: 1) duplicated reporting
(in which studies with the longest follow-up time were
selected); 2) using BMS or biodegradable polymer
DES (BP-DES) or bioabsorbable scaffold stents or
other peculiar stents. Data were abstracted on pre-
specified forms by two unblinded reviewers and di-
vergences of opinion were resolved by consensus.Quality assessment
The quality assessment was performed according to
the Cochrane handbook for systematic reviews of in-
terventions 5.1.0.7 The quality of the studies included
was appraised by two unblinded investigators. The risk
of selection, performance, detection, attrition, report-
ing and other bias was qualified as a low risk of bias,
an unclear risk of bias or a high risk of bias as rec-
ommended. The initial protocols registered in clin-
icaltrial.gov (https://clinicaltrials.gov/) were screened
when qualifying a reporting bias.
Date extraction
Two blinded reviewers independently performed
data extraction. Disagreements between the reviewers
were resolved through discussion or by the third
reviewer. The extracted data included: (1) first author's
last name, the publication year; (2) characteristics of
the study population, (3) stent types, duration of
follow-up, (4) study design, and (5) study endpoints.
Endpoints and definitions
The composite endpoint of major adverse cardio-
vascular events (MACEs) was defined as the composite
of all-cause death, MI, or ischemia-driven TLR. Defi-
nite or probable stent thrombosis was adjudicated
using the Academic Research Consortium definite or
probable criteria.8
Data analysis
Review manager 5.2.6 was used for all analyses.
Odds ratios (ORs) were computed from individual
studies and pooled according to a fixed effect or
random effect model in case of statistical heterogene-
ity. Outcomes appraised were all-cause death, MI,
TLR, MACEs, LST, and in-stent LLL. We used the
Mantel-Haenszel method for combining ORs of binary
outcomes. The mean difference of followed-up LLL
compared with baseline was used for the in-stent LLL
outcomes, and the overall weighted mean difference
(WMD) was built with the inverse variance method, as
recommended.7
We assessed the heterogeneity between eligible
studies by the Cochrane Q test. We considered P values
less than 0.10 as an indicator of significant heterogeneity
because of the low statistical power. We also used the
inconsistency index I2 to quantify heterogeneity. Funnel
plots were constructed to assess publication bias.
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Literature search and eligible studies
The review process is presented in Fig. 1. The
literature search resulted in 140 relevant outcomes
after duplicates removed. We excluded 100 reviews
and irrelevant studies, and 11 studies were removed
after closer inspection. The specific reasons for their
exclusion were: 1) non-randomized studies or regis-
tries studies, 2) used BMS or BP-DES or other
peculiar stent technologies. We excluded duplicated
reports of the same studies. Finally, we considered 11
appropriate studies, one9 of which did not provide
necessary data and it was excluded from this meta-
analysis.
The 10 studies10e19 enrolling 6575 patients were
included in the meta-analysis. Study follow-up
duration ranged from 1 to 5 years. In ISAR-TEST-
3,11 Byrne et al compared the clinical outcomes of
three different polymer coating strategies (PP-DES,
BP-DES and PF-DES), and we only extracted data
about PP-DES and PF-DES. In the ISAR-TEST-2,10
Byrne et al compared PF-DES with two types of
PP-DES, so we combined the data of the two types
of PP-DES. The risk of bias assessment is presented
in Fig. 2. There was no publication bias according
to the funnel plot of each endpoint (Fig. 3). The
main characteristics are presented in Table 1 and
Table 2.Fig. 3. Funnel plot of comparison Polymer-free drug eluting stents (PF-DE
stent late stent thrombosis. Funnel plot displays no publication bias about
absence of graphical asymmetrical distribution.Outcome analysis
All-cause death
A fixed effect model was used to build up the
quantitative analysis for all-cause death given that no
heterogeneity was found. The 10 studies that enrolled
6539 patients were included in the analysis. Compared
with PP-DES, PF-DES significantly decreased the all-
cause death rate (OR ¼ 0.77, 95% CI: 0.61 to 0.98,
P ¼ 0.03) (Fig. 4).
Myocardial infarction
A fixed effect model was used for the quantitative
analysis as we found no heterogeneity. Compared with
PP-DES, no significant benefit was found in the PF-
DES group (OR ¼ 1.12, 95% CI: 0.19 to 23.18,
P ¼ 0.39) (Fig. 5).
Target lesion revascularization
The result of TLR was available in 10 studies. We
used a fixed effect model to perform the quantitative
analysis as no heterogeneity was found. The PF-DES
group showed no significant benefit compared with
the PP-DES group (OR ¼ 1.19, 95% CI: 0.42 to 3.38,
P ¼ 0.83) (Fig. 6).
MACEs
Three of the studies met the definition of MACEs in
our analysis. In other studies, we calculated the
MACEs according to the corresponding results. AS) vs. Permanent polymer drug eluting stents (PP-DES): outcome: in-
the end-point of late stent thrombosis (LST), as demonstrated by the
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analysis. The two kinds of stents showed similar re-
sults in MACEs (OR ¼ 0.99, 95% CI: 0.79 to 1.24,
P ¼ 0.91) (Fig. 7).
Late stent thrombosis
We extracted definite or probable LST for further
analysis. A fixed effect model was used to build up the
quantitative analysis as no heterogeneity was found.
The PF-DES and the PP-DES showed similar rates of
LST (OR ¼ 0.92, 95% CI: 0.05 to 5.71, P ¼ 0.74)
(Fig. 8).
Late lumen loss
A random effect model was used to perform the
meta-analysis given the degree of heterogeneity found.
Two of the studies10,11 performed angiography twice
during follow-up (once in 6e8 month, once in 2 years),
while in three studies12e14 it was performed once in
6e9 months. We built a meta-analysis for both short
term LLL (6e9 months) and long term LLL (2 years).
In the early phases, PF-DES showed no benefit in
reducing LLL compared with PP-DES (WMD
0.03 mm 95% CI: 0.07 to 0.13 mm, P ¼ 0.57).
However, after reviewing the 2 years outcome, the PF-
DES showed a significantly lower in-stent LLL
(OR ¼ 0.77, 95% CI: 0.61 to 0.98, P ¼ 0.03) (Fig. 9).
Discussion
The main finding of this meta-analysis is that
compared with PP-DES, PF-DES showed superiority
in reducing long-term LLL and all-cause mortality,
while showed no significant benefit on short-term LLL,
MI, TLR and LST.
It has been demonstrated that vascular wall inflam-
mation may be induced after PP-DES implanted in
pigs20,21 and humans.22,23 This inflammation is consid-
ered to cause delayed intimal healing, late malapposition
and LST,24 and it may have an important etiological role
in adverse events late after stent implantation. Permanent
polymer can also aggravate neointimal atherosclerosis
compared with BMS which could induce more adverse
events.25 Considering that, intimal inflammation and
LST have become a bottleneck problem restricting the
development of DES. As a consequence, both BP-DES
and PF-DES have been the focus of and have been
developed. BP-DES showed superiority in reducing TLR
and LLL but without clear benefits for mortality, MI, and
LST.26 Nevertheless, studies also reported late inflam-
mation after BP-DES implantation.22,27
Table 2
Features of clinical trials included after full-text inspection.
Study Age (years) Male
(%)
Smoking
(%)
HBP
(%)
Dyslipidemia
(%)
Diabetes
(%)
ACS
(%)
Prior
MI
Prior
PCI
Prior
CABG
Type B2/C
lesions (%)
Lesion
length
Byrne 2009 66.0 ± 10.2 79.9 16.4 65.8 67.5 27.0 30.5 33.3 NA 10.4 NA 14.45 ± 6.14
Byrne 2010 66.9 ± 11.1 66.7 18.4 66.7 65.7 27.4 41.8 27.0 NA 8.83 72.5 14.46 ± 8.17
Carrie 2011 64.6 ± 10.3 72.1 24.5 64.4 61.9 26.9 NA 9.0 15.2 NA 31.3 15.28 ± 7.03
Dang 2012 66.2 ± 13.1 69.5 64.8 43.8 21.9 25.7 100 5.7 1.9 NA 56.7 NA
Massberg 2011 67.8 ± 11.1 76.4 17.4 66.7 63.5 29.0 41.0 29.5 NA 9.5 74.1 16.57 ± 9.74
King 2013 66.7 ± 10.3 76.9 18.2 66.0 74.4 29.1 42.9 31.8 NA 11.1 76.4 12.75 ± 6.47
Shiratori 2014 66.5 ± 9.3 72.6 18.9 73.2 61.6 32.3 42.7 31.1 28.9 6.1 73.8 15.91 ± 8.81
Stiermaier 2013 67.1 ± 9.3 68.6 25.0 97.5 NA 100 NA 22.0 30.1 7.6 36.4 16.74 ± 4.63
Zhang 2013 65.6 ± 10.8 67.0 40.0 64.8 NA 26.5 85.5 NA NA NA 87.7 NA
Zhang 2014 57.4 ± 10.4 76.8 51.6 53.5 31.1 16.8 NA 30.2 14.8 NA NA 23.6 ± 13.5
HBP: high blood pressure, ACS: acute coronary syndrome, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary
artery bypass grafting.
Fig. 4. Individual and summary odds ratios for all-causes death in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-free
drug eluting stents, PP-DES: permanent polymer drug eluting stents, MeH: Mantel-Haenszel method.
Fig. 5. Individual and summary odds ratios for myocardial infraction in patients treated by PF-DES and PP-DES implantation. PF-DES: polymer-
free drug eluting stents, PP-DES: permanent polymer drug eluting stents, MeH: Mantel-Haenszel method.
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Fig. 6. Individual and summary odds ratios for target lesion revascularization in patients treated by PF-DES and PP-DES implantation. PF-DES:
polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, MeH: Mantel-Haenszel method.
Fig. 7. Individual and summary odds ratios for major adverse cardiovascular events in patients treated by PF-DES and PP-DES implantation. PF-
DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, MeH: Mantel-Haenszel method.
Fig. 8. Individual and summary odds ratios for definite or probable late stent thrombosis in patients treated by PF-DES and PP-DES implantation.
PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, MeH: Mantel-Haenszel method.
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Fig. 9. Individual and summary odds ratios for in-stent lumen loss in patients treated by PF-DES and PP-DES implantation at short (6e9 months)
or long (2 years) term. PF-DES: polymer-free drug eluting stents, PP-DES: permanent polymer drug eluting stents, IV: inverse variance method.
228 D.-W. Wu et al. / Chronic Diseases and Translational Medicine 1 (2015) 221e230Several studies have evaluated the safety and effi-
ciency of PF-DES involving different types of stent
coating different agents including Paclitaxel,16,28
sirolimus,10,11,13e15 biolimus29 and amphilimus.12
This meta-analysis included 10 studies comparing
polymer-free paclitaxel, sirolimus and amphilimus
eluting stents with PP-DES with 1e5 years follow-up
duration. PF-DES coated with biolimus were not
included due to absence of the necessary data.
Given that two (2)10,11 of the studies didn't provide
data on cardiac death, we analyzed rates of all-cause
death to evaluate the efficiency of PF-DES in
reducing mortality. It showed that PF-DES could
significantly reduce mortality without any detectable
heterogeneity so that this may be convincing evidence
in the evaluation of PF-DES.
Another noteworthy finding of this meta-analysis
was that compared with PP-DES, PF-DES had a
similar LLL 6e9 months after stent implantation,
while it showed significant benefit in long-term follow-
up. Because of a higher speed of drug release (~75% in
the first 10 days), PF-DES may have relatively higher
initial lumen loss in 6e9 months compared with PP-
DES. However, it may consequently prompt earlier
and more complete vessel healing than PP-DES. It has
been demonstrated that additional lumen loss wasfound in PP-DES implanted vessels even beyond 6e9
months.30,31 It might also be proposed that existence of
a polymer induced more inflammation and higher
lumen loss.32
No benefit in reducing TLR, MI and LST of PF-
DES was found in this meta-analysis. Among the 10
studies, two (2) of them had a 5-year follow-up time
while the other eight (8) studies followed up for 1 or 2
years. A short duration of follow-up might make it
difficult to detect endpoints with low incidences even
though we had a large sample size. Further studies with
larger sample size and longer follow-up duration need
to be performed in the future.
Limitations
We did not have access to the data of the Bio-
freedom FIM study,9 even though we made a great
effort, and it might have been important for this
analysis. The coating agents and follow-up duration
ranged among different studies, which lead to het-
erogeneity in the analysis. Finally, we could not get
access to individual patient data which prevented us
from making subgroup analysis; such as acute coro-
nary syndrome, diabetes, and other meaningful clin-
ical conditions.
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In this meta-analysis, PF-DES showed benefit on
reducing long-term LLL and all-cause mortality
compared with PP-DES, but no superiority was found
in short-term LLL, MI, TLR and LST. These findings
provide a sound basis to wide application of PF-DES in
the future.
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